Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity
Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA tran...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/12/11/1437 |
| _version_ | 1797468940944801792 |
|---|---|
| author | Nora-Isabell Griebsch Johanna Kern Jonas Hansen Michael Rullmann Julia Luthardt Stephanie Helfmeyer Franziska J. Dekorsy Marvin Soeder Mohammed K. Hankir Franziska Zientek Georg-Alexander Becker Marianne Patt Philipp M. Meyer Arne Dietrich Matthias Blüher Yu-Shin Ding Anja Hilbert Osama Sabri Swen Hesse |
| author_facet | Nora-Isabell Griebsch Johanna Kern Jonas Hansen Michael Rullmann Julia Luthardt Stephanie Helfmeyer Franziska J. Dekorsy Marvin Soeder Mohammed K. Hankir Franziska Zientek Georg-Alexander Becker Marianne Patt Philipp M. Meyer Arne Dietrich Matthias Blüher Yu-Shin Ding Anja Hilbert Osama Sabri Swen Hesse |
| author_sort | Nora-Isabell Griebsch |
| collection | DOAJ |
| description | Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success. The study population consisted of two study cohorts using either the 5-HTT-selective radiotracer [<sup>11</sup>C]DASB to measure 5-HTT availability or the NAT-selective radiotracer [<sup>11</sup>C]MRB to assess NAT availability. Each group included non-obesity healthy participants, patients with severe obesity (body mass index, BMI, >35 kg/m<sup>2</sup>) following a conservative dietary program (diet) and patients undergoing RYGB surgery within a 6-month follow-up. Overall, changes in BMI were not associated with changes of both 5-HTT and NAT availability, while 5-HTT availability in the dorsal raphe nucleus (DRN) prior to intervention was associated with substantial BMI reduction after RYGB surgery and inversely related with modest BMI reduction after diet. Taken together, the data of our study indicate that 5-HTT and NAT are involved in the pathomechanism of obesity and have the potential to serve as predictors of treatment outcomes. |
| first_indexed | 2024-03-09T19:14:24Z |
| format | Article |
| id | doaj.art-9d3c687fa4f64d6f936cb0145ef0fa7c |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-09T19:14:24Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-9d3c687fa4f64d6f936cb0145ef0fa7c2023-11-24T03:55:57ZengMDPI AGBrain Sciences2076-34252022-10-011211143710.3390/brainsci12111437Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with ObesityNora-Isabell Griebsch0Johanna Kern1Jonas Hansen2Michael Rullmann3Julia Luthardt4Stephanie Helfmeyer5Franziska J. Dekorsy6Marvin Soeder7Mohammed K. Hankir8Franziska Zientek9Georg-Alexander Becker10Marianne Patt11Philipp M. Meyer12Arne Dietrich13Matthias Blüher14Yu-Shin Ding15Anja Hilbert16Osama Sabri17Swen Hesse18Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyIntegrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyIntegrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, GermanyIntegrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, GermanyDepartment of Experimental Surgery, University Hospital Würzburg, 97080 Würzburg, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyIntegrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, GermanyMedical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig, 04103 Leipzig, GermanyDepartments of Radiology and Psychiatry, New York University School of Medicine, New York, NY 10016, USAIntegrated Research and Treatment Center Adiposity Diseases, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanyDepartment of Nuclear Medicine, University of Leipzig, 04103 Leipzig, GermanySerotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success. The study population consisted of two study cohorts using either the 5-HTT-selective radiotracer [<sup>11</sup>C]DASB to measure 5-HTT availability or the NAT-selective radiotracer [<sup>11</sup>C]MRB to assess NAT availability. Each group included non-obesity healthy participants, patients with severe obesity (body mass index, BMI, >35 kg/m<sup>2</sup>) following a conservative dietary program (diet) and patients undergoing RYGB surgery within a 6-month follow-up. Overall, changes in BMI were not associated with changes of both 5-HTT and NAT availability, while 5-HTT availability in the dorsal raphe nucleus (DRN) prior to intervention was associated with substantial BMI reduction after RYGB surgery and inversely related with modest BMI reduction after diet. Taken together, the data of our study indicate that 5-HTT and NAT are involved in the pathomechanism of obesity and have the potential to serve as predictors of treatment outcomes.https://www.mdpi.com/2076-3425/12/11/1437obesityserotoninnoradrenalineserotonin transporternoradrenaline transporterRoux-en-Y gastric bypass surgery |
| spellingShingle | Nora-Isabell Griebsch Johanna Kern Jonas Hansen Michael Rullmann Julia Luthardt Stephanie Helfmeyer Franziska J. Dekorsy Marvin Soeder Mohammed K. Hankir Franziska Zientek Georg-Alexander Becker Marianne Patt Philipp M. Meyer Arne Dietrich Matthias Blüher Yu-Shin Ding Anja Hilbert Osama Sabri Swen Hesse Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity Brain Sciences obesity serotonin noradrenaline serotonin transporter noradrenaline transporter Roux-en-Y gastric bypass surgery |
| title | Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity |
| title_full | Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity |
| title_fullStr | Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity |
| title_full_unstemmed | Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity |
| title_short | Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity |
| title_sort | central serotonin noradrenaline transporter availability and treatment success in patients with obesity |
| topic | obesity serotonin noradrenaline serotonin transporter noradrenaline transporter Roux-en-Y gastric bypass surgery |
| url | https://www.mdpi.com/2076-3425/12/11/1437 |
| work_keys_str_mv | AT noraisabellgriebsch centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT johannakern centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT jonashansen centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT michaelrullmann centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT julialuthardt centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT stephaniehelfmeyer centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT franziskajdekorsy centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT marvinsoeder centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT mohammedkhankir centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT franziskazientek centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT georgalexanderbecker centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT mariannepatt centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT philippmmeyer centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT arnedietrich centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT matthiasbluher centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT yushinding centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT anjahilbert centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT osamasabri centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity AT swenhesse centralserotoninnoradrenalinetransporteravailabilityandtreatmentsuccessinpatientswithobesity |